CIK 0001815442
- Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812992166
- Phone
- +1 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 68 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | Gollob Jared Chief Medical Officer | Grant or award | +24,375 | 99,084 | ||
| 2024-03-01 | Gollob Jared Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +146,250 | 146,250 | ||
| 2024-03-01 | Chadwick Jeremy G Chief Operating Officer | Grant or award | +13,425 | 46,758 | ||
| 2024-03-01 | Chadwick Jeremy G Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +80,548 | 80,548 | ||
| 2024-03-01 | Chiniara Ellen Chief Legal Officer | Grant or award | +21,755 | 55,960 | ||
| 2024-03-01 | Chiniara Ellen Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +130,531 | 130,531 | ||
| 2024-03-01 | Mainolfi Nello Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +530,000 | 530,000 | ||
| 2024-03-01 | Jacobs Bruce N. Chief Financial Officer | Grant or award | +31,250 | 146,285 | ||
| 2024-03-01 | Jacobs Bruce N. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +187,500 | 187,500 | ||
| 2024-02-27 | Gollob Jared Chief Medical Officer | Exercise or conversion 10b5-1 | +400 | $2.08 | $832 | 75,109 |
| 2024-02-27 | Gollob Jared Chief Medical Officer | Sale 10b5-1 | −400 | $45.00 | $18K | 74,709 |
| 2024-02-27 | Gollob Jared Chief Medical Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −400 | 62,483 | ||
| 2024-02-21 | Albers Jeffrey W. Director | Exercise or conversion 10b5-1 | +4,385 | $10.34 | $45K | 4,385 |
| 2024-02-21 | Albers Jeffrey W. Director | Sale 10b5-1 | −4,385 | $39.05 | $171K | 0 |
| 2024-02-21 | Albers Jeffrey W. Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −4,385 | 16,349 | ||
| 2024-02-20 | Albers Jeffrey W. Director | Exercise or conversion 10b5-1 | +615 | $10.34 | $6K | 615 |
| 2024-02-20 | Albers Jeffrey W. Director | Sale 10b5-1 | −615 | $39.07 | $24K | 0 |
| 2024-02-20 | Albers Jeffrey W. Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −615 | 20,734 | ||
| 2024-02-09 | Gollob Jared Chief Medical Officer | Exercise or conversion 10b5-1 | +46,137 | $2.08 | $96K | 120,846 |
| 2024-02-09 | Gollob Jared Chief Medical Officer | Sale 10b5-1 | −38,739 | $35.39 | $1.4M | 82,107 |
Page 30 of 41 · 810 trades